Loading...

Brilliant Violet 605™ anti-mouse/human CD11b Antibody

Pricing & Availability
Clone
M1/70 (See other available formats)
Regulatory Status
RUO
Other Names
αM integrin, Mac-1, Mo1, CR3, Ly-40, C3biR, ITGAM
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
M1slash70_BV605_020212
C57BL/6 mouse bone marrow cells were stained with CD11b (clone M1/70) Brilliant Violet 605™. Data shown was gated on myeloid cell population.
  • M1slash70_BV605_020212
    C57BL/6 mouse bone marrow cells were stained with CD11b (clone M1/70) Brilliant Violet 605™. Data shown was gated on myeloid cell population.
See Brilliant Violet 605™ spectral data
Cat # Size Price Quantity Check Availability Save
101237 125 µL $209
Check Availability


Need larger quantities of this item?
Request Bulk Quote
101257 50 µg $257
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD11b is a 170 kD glycoprotein also known as αM integrin, Mac-1 α subunit, Mol, CR3, and Ly-40. CD11b is a member of the integrin family, primarily expressed on granulocytes, monocytes/macrophages, dendritic cells, NK cells, and subsets of T and B cells. CD11b non-covalently associates with CD18 (β2 integrin) to form Mac-1. Mac-1 plays an important role in cell-cell interaction by binding its ligands ICAM-1 (CD54), ICAM-2 (CD102), ICAM-4 (CD242), iC3b, and fibrinogen.

Product Details
Technical data sheet

Product Details

Reactivity
Mouse,Human,Cynomolgus,Rhesus
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
C57BL/10 splenocytes
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the µg size, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. For flow cytometric staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Clone M1/70 has been verified for immunocytochemistry (ICC) and frozen immunohistochemistry (IHC-F).

Additional reported applications (for relevant formats of this clone) include: immunoprecipitation1,4, in vitro blocking3,9,12, depletion2,8, immunofluorescence microscopy6,7,10, immunohistochemistry of acetone-fixed frozen sections5,11-13, and spatial biology (IBEX)35,36. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) (Cat. No. 101248).

Application References

(PubMed link indicates BioLegend citation)
  1. Springer T, et al. 1978. Eur. J. Immunol. 8:539. (IP)
  2. Ault K and Springer T. 1981. J. Immunol. 126:359. (Deplete)
  3. Springer TA, et al. 1982. Immunol. Rev. 68:171. (Block)
  4. Ho MK and Springer TA. 1983. J. Biol. Chem. 258:2766. (IP)
  5. Flotte TJ, et al. 1983. Am. J. Pathol. 111:112. (IHC)
  6. Noel GJ, et al. 1990. J. Clin. Invest. 85:208. (IF)
  7. Allen LA and Aderem A. 1996. J. Exp. Med. 184:627 (IF)
  8. D'Amico A and Wu L. 2003. J. Exp. Med. 198:293. (Deplete)
  9. Brickson SJ, et al. 2003. Appl Physiol. 95:969. (Block)
  10. Clatworthy MR and Smith KG. 2004. J. Exp. Med. 199:717. (IF)
  11. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  12. Zhang Y, et al. 2002. J. Immunol. 168:3088. (IHC)
  13. Iwasaki A and Kelsall BL. 2001. J. Immunol. 166:4884 (IHC, FC)
  14. Tailleux L. 2003. J. Exp. Med. 197:121. (Block, FC)
  15. Olver S, et al. 2006. Cancer Research 66:571. (FC)
  16. Tan SL, et al. 2006. J. Immunol. 176:2872. (FC) PubMed
  17. Ponomarev ED, et al. 2006. J. Immunol. 176:1402. (FC)
  18. Dzhagalov I, et al. 2007. Blood 109:1620. (FC)
  19. Fazilleau N, et al. 2007. Nature Immunol. 8:753.
  20. Rasmussen JW, et al. 2006. Infect. Immun.74:6590. PubMed
  21. Napimoga MH, et al. 2008. J. Immunol. 180:609. PubMed
  22. Elqaraz-Carmon V, et al. 2008. J. Lipid. Res. 49:1894. PubMed
  23. Kim DD, et al. 2008. Blood 112:1109. PubMed
  24. Guo Y, et al. 2008. Blood 112:480. PubMed
  25. Norian LA, et al. 2009. Cancer Res. 69:3086. (FC) PubMed
  26. Baumgartner CK, et al. 2010. J. Immunol. 184:573. PubMed
  27. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  28. Whiteland J, et al. 1995. J. Histochem. Cytochem. 43:313. (IHC)
  29. Weber GF, et al. 2014. J Exp Med. 211:1243. PubMed
  30. Ashok A, et al. 2015. Toxicol Sci. 143:64. PubMed
  31. Price PJ, et al. 2015. J Immunol. 194:1164. PubMed
  32. Doni A, et al. 2015. J Exp Med. 212:905. PubMed
  33. Ferreira R, et al. 2016. J Infect Dis. 213: 669 - 673. PubMed
  34. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
  35. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  36. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Cohen M et al. 2018. Cell. 175(4):1031-1044 . PubMed
  2. Campbell C et al. 2018. Immunity. 48(6):1245-1257 . PubMed
  3. White JP et al. 2018. Cell. 175(5):1198-1212 . PubMed
  4. Linehan JL et al. 2018. Cell. 172(4):784-796 . PubMed
  5. Sheng W et al. 2018. Cell. 174(3):549-563 . PubMed
  6. Macal M et al. 2018. Immunity. 48(4):730-744 . PubMed
  7. Michela Miani et al. 2018. Cell metabolism. 28(4):557-572 . PubMed
  8. Zhu YP et al. 2018. Cell reports. 24(9):2329-2341 . PubMed
  9. Pinho–Ribeiro FA, et al. 2018. Cell. 173:1083. PubMed
  10. Tordesillas L, et al. 2018. Nat Commun. 9:5238. PubMed
  11. Martínez‐López M et al. 2019. Immunity. 50(2):446-461 . PubMed
  12. Tavazoie MF, et al. 2018. Cell. 172:825. PubMed
  13. Frank AC, et al. 2019. Nat Commun. 10:1135. PubMed
  14. Bretou M, et al. 2017. Sci Immunol. 2:16. PubMed
  15. Han Y et al. 2019. Cell reports. 27(3):835-846 . PubMed
  16. Schmidleithner L et al. 2019. Immunity. 50(5):1232-1248 . PubMed
  17. Bommareddy PK, et al. 2019. J Biol Methods. 6:2. PubMed
  18. Merz SF, et al. 2019. Nat Commun. 10:2312. PubMed
  19. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  20. McBride KM, et al. 2019. Front Oncol. 9:517. PubMed
  21. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  22. Karlen SJ, et al. 2018. J Neuroinflammation. 15:344. PubMed
  23. Yang H, et al. 2019. J Neuroinflammation. 16:169. PubMed
  24. Tran NT, et al. 2019. Cell Rep. 28:3510. PubMed
  25. Sparber F et al. 2019. British journal of pharmacology. 176(11):1728-1744 . PubMed
  26. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  27. Christopher S Garris et al. 2018. Immunity. 49(6):1148-1161 . PubMed
  28. Saha D et al. 2017. Cancer cell. 32(2):253-267 . PubMed
  29. Sun T, et al. 2017. Mucosal Immunol. 0.954861111. PubMed
  30. Urata S, et al. 2018. PLoS Pathog. 14:e1007172. PubMed
  31. O'Boyle C, et al. 2020. Int J Stroke. 0.746527778. PubMed
  32. Iwahori K, et al. 2019. Sci Rep. 2.205555556. PubMed
  33. Chan YH, et al. 2019. EMBO Mol Med. 11:e10092. PubMed
  34. Yousef H, et al. 2019. Nat Med. 25:988. PubMed
  35. Garber C, et al. 2019. Nat Neurosci. 1.802777778. PubMed
  36. Godwin MS, et al. 2019. JCI Insight. 4:e126070. PubMed
  37. Bonnardel J, et al. 2019. Immunity. 51:638. PubMed
  38. Piper CJM, et al. 2020. Cell Reports. 29(7):1878-1892.e7.. PubMed
  39. Rosser EC, et al. 2020. Cell Metabolism. 31(4):837-851. PubMed
  40. Lai NY, et al. 2020. Cell. 180:33:00. PubMed
  41. Dudeck J, et al. 2019. J Allergy Clin Immunol. 143:1849. PubMed
  42. Niss K, et al. 2020. Cell Reports. 31(11):107763. PubMed
  43. Branchett WJ, et al. 2020. Wellcome Open Research. 0.278472222. PubMed
  44. Iannello A, et al. 2013. J Exp Med. 210:2057. PubMed
  45. Wang T, et al. 2015. Proc Natl Acad Sci U S A. 112:440. PubMed
  46. Herz J, et al. 2015. J Exp Med. 212: 1153 - 1169. PubMed
  47. Rosenheinrich M, et al. 2015. PLoS One. 10: 0136290. PubMed
  48. Ray A, et al. 2015. PLoS One. 10: 0137314. PubMed
  49. Shi H, et al. 2015. Nat Immunol. . PubMed
  50. Crichton M, et al. 2016. Sci Rep. 6:27217. PubMed
  51. Swanson P, et al. 2016. PLoS Pathog. 12:e1006022. PubMed
  52. C Khouili S, et al. 2020. Cell Rep. 33:108468. PubMed
  53. Goh W, et al. 2020. Cell Rep. 33:108285. PubMed
  54. Gallizioli M, et al. 2020. Cell Rep. 33:108291. PubMed
  55. Si Y, et al. 2020. Sci Adv. 6:eaba0995. PubMed
  56. Morris MG, et al. 2020. Comp Med. 70:336. PubMed
  57. Wang YT, et al. 2020. Nat Microbiol. 0.397222222. PubMed
  58. Mansouri S, et al. 2020. Mucosal Immunol. 0.954861111. PubMed
  59. Ruhland MK, et al. 2020. Cancer Cell. 37(6):786-799.e5. PubMed
  60. Xu C, et al. 2020. Immunity. 53(2):417-428.e4. PubMed
  61. Hamaidi I, et al. 2020. Cell Metabolism. 32(3):420-436.e12. PubMed
  62. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  63. Srivastava S, et al. 2020. Cancer Cell. 39(2):193-208.e10. PubMed
  64. Deerhake ME, et al. 2021. Immunity. 54(3):484-498.e8. PubMed
  65. Tacconi C, et al. 2021. Cell Reports. 35(2):108993. PubMed
  66. Wang C, et al. 2021. Cell Stem Cell. . PubMed
  67. Dieterich LC, et al. 2019. International Journal of Cancer. 145(10):2804-2815. PubMed
  68. Zhao B, et al. 2021. Cell Reports. 36(3):109401. PubMed
  69. Montalban-Arques A, et al. 2021. Cell Host Microbe. :. PubMed
  70. Webster HC, et al. 2020. J Immunol Methods. 112702:477. PubMed
  71. Alam Z, et al. 2020. Cell Rep. 107825:31. PubMed
  72. Macpherson L, et al. 2020. Nature. 577:266. PubMed
  73. Ostendorf BN, et al. 2020. Nat Med. 26:1048. PubMed
  74. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  75. Frank AC, et al. 2021. Theranostics. 11:7570. PubMed
  76. Rodriguez-García A, et al. 2021. Nat Commun. 12:877. PubMed
  77. Song J, et al. 2021. J Am Heart Assoc. 10:e017329. PubMed
  78. Pan Y, et al. 2021. Front Cell Neurosci. 15:664312. PubMed
  79. Matei DE, et al. 2021. Med (N Y). 2:864. PubMed
  80. Chao JL, et al. 2021. Cell Rep Med. 2:100399. PubMed
  81. Marchelletta RR, et al. 2021. J Clin Invest. 131:. PubMed
  82. Li X, et al. 2021. Front Immunol. 12:779560. PubMed
  83. Gómez-Díaz C, et al. 2021. iScience. 24:103241. PubMed
  84. Liu Y, et al. 2021. Nat Commun. 12:6831. PubMed
  85. Stotesbury C, et al. 2020. J Immunol. 204:1582. PubMed
  86. Ma J, et al. 2020. Adv Sci (Weinh). 7:2000609. PubMed
  87. Boal-Carvalho I, et al. 2020. EMBO Rep. 21:e50421. PubMed
  88. Jong RM, et al. 2022. J Immunol. 208:407. PubMed
  89. Dar HH, et al. 2022. JCI Insight. 7:. PubMed
  90. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  91. Yang C, et al. 2022. Research (Wash D C). 2022:9768687. PubMed
  92. Chen WS, et al. 2021. Cell Rep. 37:109974. PubMed
  93. Melhem NJ, et al. 2021. Circulation. 143:566. PubMed
  94. Ferrere G, et al. 2021. JCI Insight. 6:. PubMed
  95. Hu J, et al. 2021. Sci Adv. 7:. PubMed
  96. Kastenschmidt JM, et al. 2021. Cell Rep. 35:108997. PubMed
  97. Nam J, et al. 2021. Adv Ther (Weinh). 4:. PubMed
  98. Fearon AE, et al. 2021. iScience. 24:103143. PubMed
  99. Rivera CA, et al. 2022. Immunity. 55:129. PubMed
  100. Rive CM, et al. 2022. Mol Ther Methods Clin Dev. 26:4. PubMed
  101. Aktories P, et al. 2022. Cell Rep Methods. 2:100260. PubMed
  102. Stotesbury C, et al. 2020. Aging Cell. 19:e13170. PubMed
  103. Huard A, et al. 2021. J Immunol. 206:1058. PubMed
  104. Luo M, et al. 2021. J Immunol. 207:1683. PubMed
  105. Hu W, et al. 2021. Nat Immunol. 22:1163. PubMed
  106. Coleby R, et al. 2021. Clin Exp Rheumatol. :39. PubMed
  107. Mujal AM, et al. 2022. Cancer Immunol Res. 10:403. PubMed
  108. Rosen SF, et al. 2022. Genome Med. 14:108. PubMed
  109. Zeng Q, et al. 2022. iScience. 25:105151. PubMed
  110. Bauer KM, et al. 2022. JCI Insight. 7:. PubMed
  111. Li Y, et al. 2022. J Neuroinflammation. 19:261. PubMed
  112. Seenappa LM, et al. 2022. NPJ Vaccines. 7:128. PubMed
  113. Bratti M, et al. 2022. Front Immunol. 13:1029759. PubMed
  114. Li N, et al. 2022. Nat Commun. 13:7281. PubMed
  115. Pohlmeier L, et al. 2021. Allergy. 76:2030. PubMed
  116. Duraiswamy J, et al. 2021. Cancer Cell. 39:1623. PubMed
  117. Xin B, et al. 2022. Hepatology. 76:630. PubMed
  118. Alam A, et al. 2022. Cancer Cell. 40:153. PubMed
  119. McCauley KE, et al. 2022. Cell Rep Med. 3:100713. PubMed
  120. Mansouri S, et al. 2022. J Immunol. 209:2114. PubMed
  121. Cousin N, et al. 2022. Cells. 12: . PubMed
  122. Arimoto KI, et al. 2023. Nat Commun. 14:251. PubMed
  123. Dickerson KM, et al. 2022. Blood Cancer Discov. 3:240. PubMed
  124. Harapas CR, et al. 2022. Sci Immunol. 7:eabi4611. PubMed
  125. Christian DA, et al. 2022. Sci Immunol. 7:eabq7432. PubMed
  126. Bonifacio JPPL, et al. 2022. J Virol. 96:e0087122. PubMed
  127. Skladanowska K, et al. 2022. Cell Rep. 41:111490. PubMed
  128. Deák P, et al. 2022. Cell Rep. 41:111563. PubMed
  129. Jia DJ, et al. 2022. Gut Microbes. 14:2145843. PubMed
  130. Chen LC, et al. 2023. Immunology. 169:271. PubMed
  131. Palakurthi B, et al. 2023. Nat Commun. 14:2109. PubMed
  132. Zhang AQ, et al. 2023. Nat Biomed Eng. . PubMed
  133. Oh J, et al. 2023. Nat Commun. 14:3278. PubMed
RRID
AB_11126744 (BioLegend Cat. No. 101237)
AB_2565431 (BioLegend Cat. No. 101257)

Antigen Details

Structure
Integrin family, associates with integrin β2 (CD18), 170 kD
Distribution

Granulocytes, monocytes/macrophages, dendritic cells, NK cells, subsets of T and B cells

Function
Adhesion, chemotaxis
Ligand/Receptor
ICAM-1 (CD54), ICAM-2 (CD102), ICAM-4 (CD242), iC3b, fibrinogen
Cell Type
B cells, Dendritic cells, Granulocytes, Macrophages, Monocytes, Neutrophils, NK cells, T cells, Tregs
Biology Area
Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity, Neuroscience, Neuroscience Cell Markers
Molecular Family
Adhesion Molecules, CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Springer TA. 1994. Cell 76:301.
3. Coxon A, et al. 1996. Immunity 5:653.

Gene ID
16409 View all products for this Gene ID 3684 View all products for this Gene ID
UniProt
View information about CD11b on UniProt.org
Go To Top Version: 1    Revision Date: 11/30/2012

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login/Register
Remember me
Forgot your password? Reset Password
Request an Account